Immix Biopharma, Inc.IMMXNASDAQ
Loading
P/E Ratio: Premium ValuationElevated
Percentile Rank80
Studio
Year-over-Year Change

Price-to-earnings ratio

Latest
-2.88
↑ 67% vs avg
Percentile
P80
Within normal range
Streak
1 yr
Consecutive growthElevated
Average
-8.77
Historical baseline
PeriodValueYoY Change
2024-2.88+63.0%
2023-7.78-101.3%
2022-3.86-620.7%
2021-0.54+97.8%
2020-24.85-95.2%
2019-12.73-